Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 1/2020

Content (16 Articles)

Open Access Cancer Immunotherapy Review

Mechanisms of immune evasion in bladder cancer

Paul L. Crispen, Sergei Kusmartsev

Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody

Ryota Shibaki, Shuji Murakami, Yuji Matsumoto, Tatsuya Yoshida, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Nobuyuki Yamamoto, Masahiko Kusumoto, Noboru Yamamoto, Yuichiro Ohe

Respiratory Microbiota Original Article

Characterization of tumor-infiltrating immune cells in relation to microbiota in colorectal cancers

Tomohiro Kikuchi, Kosaku Mimura, Mai Ashizawa, Hirokazu Okayama, Eisei Endo, Katsuharu Saito, Wataru Sakamoto, Shotaro Fujita, Hisahito Endo, Motonobu Saito, Tomoyuki Momma, Zenichiro Saze, Shinji Ohki, Kazunori Shimada, Kiyoshi Yoshimura, Takuya Tsunoda, Koji Kono

Open Access Ovarian Cancer Original Article

VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer

Liju Zong, Yuncan Zhou, Ming Zhang, Jie Chen, Yang Xiang

Breast Cancer Original Article

Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells

Yeni Romero, Randi Wise, Anna Zolkiewska

Colorectal Cancer Original Article

Interleukin-38 in colorectal cancer: a potential role in precision medicine

Feier Chen, Feng Zhang, Zhenyu Tan, Brett D. Hambly, Shisan Bao, Kun Tao

Glioma Original Article

GCN2 is essential for CD8+ T cell survival and function in murine models of malignant glioma

Aida Rashidi, Jason Miska, Catalina Lee-Chang, Deepak Kanojia, Wojciech K. Panek, Aurora Lopez-Rosas, Peng Zhang, Yu Han, Ting Xiao, Katarzyna C. Pituch, Julius W. Kim, Mahsa Talebian, Jawad Fares, Maciej S. Lesniak

Original Article

Tailoring early-phase clinical trial design to address multiple research objectives

Nolan A. Wages, Craig L. Slingluff Jr., Timothy N. Bullock, Gina R. Petroni

Metastasis Original Article

CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1

Nuray Erin, Sayra Dilmaç, Anna Curry, Özlem Duymuş, Gamze Tanriover, Aaron Prodeus, Jean Gariepy, Reginald M. Gorczynski

Metastasis Original Article

IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/p-STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment

Chunyan Yu, Xiulong Niu, Yongrui Du, Yan Chen, Xiaomei Liu, Lingling Xu, Yoichiro Iwakura, Xiaoxia Ma, Yan Li, Zhi Yao, Weimin Deng

Lung Cancer Original Article

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer

Yuki Ozaki, Satoshi Muto, Hironori Takagi, Masayuki Watanabe, Takuya Inoue, Mitsuro Fukuhara, Takumi Yamaura, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Ohsugi, Mika Hoshino, Yutaka Shio, Daisuke Tanaka, Hideaki Nanamiya, Jun-ichi Imai, Takao Isogai, Shinya Watanabe, Hiroyuki Suzuki

Open Access Original Article

Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

Rui Zhang, Fengjiao Yuan, Yang Shu, Yaomei Tian, Bailing Zhou, Linglu Yi, Xueyan Zhang, Zhenyu Ding, Heng Xu, Li Yang

Filgrastim Original Article

Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer

Johanna Waidhauser, Anja Schuh, Martin Trepel, Ann-Kristin Schmälter, Andreas Rank

Open Access Correction

Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy

Nadia Mensali, Marit Renée Myhre, Pierre Dillard, Sylvie Pollmann, Gustav Gaudernack, Gunnar Kvalheim, Sébastien Wälchli, Else Marit Inderberg

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine